The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.
Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication.
Patients who complete treatment will enter 4 weeks follow-up period.
Protocol Amendment History
72 amendments
This ClinicalTrials.gov record has been amended 72 times since 2019-05-14; most recent amendment 2026-07-27.
Status change: Recruiting → Active, Not Recruiting2025-10-20
Status change: Not Yet Recruiting → Recruiting2019-10-10